

CSL Research Acceleration Initiative

Applications close 15th December, 2019

CSL and the Universities of Marburg, Giessen and the MPI-HLR wish to establish new collaborative partnerships to accelerate research.

Eligibility: Researchers/clinicians employed by the Universities of Marburg or Giessen or the MPI-HLR working in a Therapeutic Area and a Focus Area and/or Modality listed below.

Visit <https://www.cslbehring.ch/RAIMarburgGiessen> to download the application form, and submit by Sunday 15th December 2019.

THERAPEUTIC AREAS

- Immunology
- Neurology
- Haematology
- Thrombosis
- Transplant
- Respiratory
- Cardiovascular /
Metabolic

FOCUS AREAS

- Novel drug targets
- Clinical sample and/or clinical data collaborations
- Novel platforms or technologies relevant to CSL Therapeutic Area or Modality
- Novel delivery strategies and enhancements for biologics, gene or cell therapies
- Biomarkers of disease
- New uses for CSL's pipeline or on-market products

MODALITIES

- Antibodies
- Protein therapeutics
- Gene therapies
- Cell therapies
- Small molecules **not** of interest

WHY COLLABORATE WITH CSL?



Collaborate with one of the world's leading biopharmaceutical companies



Global capabilities on your doorstep



Access to commercial R&D, clinical, intellectual property, marketing and manufacturing expertise



Accelerate translation of your research to deliver new **life-saving therapies** to patients



Funding for successful proposals

For further information, please visit the link above.
Alternatively, you can email marco.cavallari@cslbehring.com.